R75251 in prostate cancer patients in progression after first-line hormonal treatment

F. Boccardo, D. Cannata, D. Guarneri, F. Oneto, E. Cortesi, A. Bono

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: The therapeutic potential of R75251, a ketoconazole derivative which has shown marked antitumor activity in animals and in men, was investigated in 16 patients with advanced prostatic cancer progressing after one or more lines of hormone therapy. Patients and methods: Patients were given the drug at 150 mg/b.i.d. for one month. After the first month of treatment, the dose was increased to 300 mg/b.i.d. In all patients, treatment was continued until disease progression or the development of severe toxicity. Clinical and biochemical assessments were performed on days 0, 14 and 28 and then repeated on a monthly basis. Results: Of the 13 evaluable patients, 12 showed stable disease by strictly employing US-NPCP criteria. However, in 3 patients a clear effect was observed on the volume of their measurable lesions. In addition, 2 of them showed a more than 50% decrease of prostate-specific antigens (PSA). Overall, 50% of patients showed some decrease in PSA baseline levels. Overall tolerance to treatment was good. Conclusions: Our results, although achieved in a small number of patients, suggest that R75251 has a moderate but definite activity in patients with hormone-refractory prostate cancer and that the value of this drug as second-line treatment in these patients should be further investigated.

Original languageEnglish
Pages (from-to)276-279
Number of pages4
JournalTumori
Volume80
Issue number4
Publication statusPublished - 1994

Fingerprint

liarozole
Prostatic Neoplasms
Therapeutics
Prostate-Specific Antigen
Hormones
Ketoconazole

Keywords

  • hormone resistance
  • hormone therapy
  • prostatic cancer
  • R75251
  • relapsing prostatic cancer

ASJC Scopus subject areas

  • Cancer Research

Cite this

Boccardo, F., Cannata, D., Guarneri, D., Oneto, F., Cortesi, E., & Bono, A. (1994). R75251 in prostate cancer patients in progression after first-line hormonal treatment. Tumori, 80(4), 276-279.

R75251 in prostate cancer patients in progression after first-line hormonal treatment. / Boccardo, F.; Cannata, D.; Guarneri, D.; Oneto, F.; Cortesi, E.; Bono, A.

In: Tumori, Vol. 80, No. 4, 1994, p. 276-279.

Research output: Contribution to journalArticle

Boccardo, F, Cannata, D, Guarneri, D, Oneto, F, Cortesi, E & Bono, A 1994, 'R75251 in prostate cancer patients in progression after first-line hormonal treatment', Tumori, vol. 80, no. 4, pp. 276-279.
Boccardo F, Cannata D, Guarneri D, Oneto F, Cortesi E, Bono A. R75251 in prostate cancer patients in progression after first-line hormonal treatment. Tumori. 1994;80(4):276-279.
Boccardo, F. ; Cannata, D. ; Guarneri, D. ; Oneto, F. ; Cortesi, E. ; Bono, A. / R75251 in prostate cancer patients in progression after first-line hormonal treatment. In: Tumori. 1994 ; Vol. 80, No. 4. pp. 276-279.
@article{a2d1eda48b8a4a889afc81bd69ac3e30,
title = "R75251 in prostate cancer patients in progression after first-line hormonal treatment",
abstract = "Introduction: The therapeutic potential of R75251, a ketoconazole derivative which has shown marked antitumor activity in animals and in men, was investigated in 16 patients with advanced prostatic cancer progressing after one or more lines of hormone therapy. Patients and methods: Patients were given the drug at 150 mg/b.i.d. for one month. After the first month of treatment, the dose was increased to 300 mg/b.i.d. In all patients, treatment was continued until disease progression or the development of severe toxicity. Clinical and biochemical assessments were performed on days 0, 14 and 28 and then repeated on a monthly basis. Results: Of the 13 evaluable patients, 12 showed stable disease by strictly employing US-NPCP criteria. However, in 3 patients a clear effect was observed on the volume of their measurable lesions. In addition, 2 of them showed a more than 50{\%} decrease of prostate-specific antigens (PSA). Overall, 50{\%} of patients showed some decrease in PSA baseline levels. Overall tolerance to treatment was good. Conclusions: Our results, although achieved in a small number of patients, suggest that R75251 has a moderate but definite activity in patients with hormone-refractory prostate cancer and that the value of this drug as second-line treatment in these patients should be further investigated.",
keywords = "hormone resistance, hormone therapy, prostatic cancer, R75251, relapsing prostatic cancer",
author = "F. Boccardo and D. Cannata and D. Guarneri and F. Oneto and E. Cortesi and A. Bono",
year = "1994",
language = "English",
volume = "80",
pages = "276--279",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4",

}

TY - JOUR

T1 - R75251 in prostate cancer patients in progression after first-line hormonal treatment

AU - Boccardo, F.

AU - Cannata, D.

AU - Guarneri, D.

AU - Oneto, F.

AU - Cortesi, E.

AU - Bono, A.

PY - 1994

Y1 - 1994

N2 - Introduction: The therapeutic potential of R75251, a ketoconazole derivative which has shown marked antitumor activity in animals and in men, was investigated in 16 patients with advanced prostatic cancer progressing after one or more lines of hormone therapy. Patients and methods: Patients were given the drug at 150 mg/b.i.d. for one month. After the first month of treatment, the dose was increased to 300 mg/b.i.d. In all patients, treatment was continued until disease progression or the development of severe toxicity. Clinical and biochemical assessments were performed on days 0, 14 and 28 and then repeated on a monthly basis. Results: Of the 13 evaluable patients, 12 showed stable disease by strictly employing US-NPCP criteria. However, in 3 patients a clear effect was observed on the volume of their measurable lesions. In addition, 2 of them showed a more than 50% decrease of prostate-specific antigens (PSA). Overall, 50% of patients showed some decrease in PSA baseline levels. Overall tolerance to treatment was good. Conclusions: Our results, although achieved in a small number of patients, suggest that R75251 has a moderate but definite activity in patients with hormone-refractory prostate cancer and that the value of this drug as second-line treatment in these patients should be further investigated.

AB - Introduction: The therapeutic potential of R75251, a ketoconazole derivative which has shown marked antitumor activity in animals and in men, was investigated in 16 patients with advanced prostatic cancer progressing after one or more lines of hormone therapy. Patients and methods: Patients were given the drug at 150 mg/b.i.d. for one month. After the first month of treatment, the dose was increased to 300 mg/b.i.d. In all patients, treatment was continued until disease progression or the development of severe toxicity. Clinical and biochemical assessments were performed on days 0, 14 and 28 and then repeated on a monthly basis. Results: Of the 13 evaluable patients, 12 showed stable disease by strictly employing US-NPCP criteria. However, in 3 patients a clear effect was observed on the volume of their measurable lesions. In addition, 2 of them showed a more than 50% decrease of prostate-specific antigens (PSA). Overall, 50% of patients showed some decrease in PSA baseline levels. Overall tolerance to treatment was good. Conclusions: Our results, although achieved in a small number of patients, suggest that R75251 has a moderate but definite activity in patients with hormone-refractory prostate cancer and that the value of this drug as second-line treatment in these patients should be further investigated.

KW - hormone resistance

KW - hormone therapy

KW - prostatic cancer

KW - R75251

KW - relapsing prostatic cancer

UR - http://www.scopus.com/inward/record.url?scp=0028054077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028054077&partnerID=8YFLogxK

M3 - Article

C2 - 7526509

AN - SCOPUS:0028054077

VL - 80

SP - 276

EP - 279

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4

ER -